FDA
-
-
-
-
-
-
-
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
-
-
-
-
-
-
-
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
-
-
-
-
-
-
-
Ocugen Provides Business Update with First Quarter 2023 Financial Results
-
-
-
-
-
-
-
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
-
-
-
-
-
-
-
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
-
-
-
-
-
-
-
Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer
-
-
-
-
-
-
-
Ocugen (OCGN) Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN
-
251,865 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All